-
The Joint Commission requires a "thorough and credible" root cause analysis (RCA) for all Sentinel Events, but the process is sometimes less effective than hoped. Quality leaders at the Mayo Clinic came up with a novel solution: An oversight group to keep the process on track.
-
With the arrival of the Centers for Medicare & Medicaid's no-pay rules, The Joint Commission's National Patient Safety Goals, and the ever-growing emphasis on quality improvement on patient care, prevention has become the name of the game.
-
-
Newcomb and colleagues reported breast cancer mortality in the Collaborative Breast Cancer Study Cohort, a prospective cohort of 12,269 postmenopausal women from Wisconsin, Massachusetts, or New Hampshire.
-
In this issue: Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.
-
-
Fetal fibronectin is now being used in many hospitals to separate out those with preterm contractions (PTCs) who are in true labor from those with contractions who are not (and, therefore, not requiring tocolytics or hospitalization).
-
The objective of this study was to examine and compare the clinical behavior and outcome of uterine carcinosarcoma relative to grade 3 endometrioid carcinoma.
-
The lift study (Long-Term Intervention on Fractures with Tibolone) was a randomized, placebo-controlled multicenter trial in 22 countries of tibolone, 1.25 mg, given daily over 3 years.
-
What often are called "compassionate use" drugs are investigational new drugs (INDs) in later phase trials where the FDA has allowed the sponsor to apply for an individual treatment IND.